Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.50 |
| ▸ | NAMPT | P43490 | 7/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | FASN | P49327 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5471824 | 0.86 | CCR2 (0.48) | HRH3NAMPTFASNCYP3A4CYP2D6 | |
| SCHEMBL5465779 | 0.85 | HRH3 (0.58) | HRH3FASNCYP2D6 | |
| SCHEMBL4772427 | 0.83 | CCR2 (0.46) | HRH3NAMPTFASNCYP3A4CYP2D6 | |
| SCHEMBL5461631 | 0.82 | CCR2 (0.52) | HRH3NAMPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL14440719 | 0.81 | NAMPT (0.44) | HRH3NAMPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL5464234 | 0.81 | SMN1; SMN2 (0.51) | HRH3NAMPTMCHR1CYP2C19 | |
| SCHEMBL4765645 | 0.80 | NPC1 (0.53) | HRH3NAMPTMCHR1CYP3A4CYP2D6 | |
| SCHEMBL4770797 | 0.78 | HRH3 (0.55) | HRH3HRH1 | |
| SCHEMBL4765684 | 0.78 | NAMPT (0.47) | HRH3NAMPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL4767921 | 0.77 | NPC1 (0.56) | HRH3NAMPTMCHR1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | CNR2, GRIN2C, GRIN2B | HRH3 38/4885NAMPT 4183/4885HRH1 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.